Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Increased Intracranial Pressure ll: Pathophysiology01:29

Increased Intracranial Pressure ll: Pathophysiology

Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins with...
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
Increased Intracranial Pressure l: Introduction01:14

Increased Intracranial Pressure l: Introduction

Intracranial hypertension is a sustained elevation of intracranial pressure (ICP) above 22 mm Hg. In supine adults, normal ICP is ~7–15 mm Hg.The rigid, nonexpandable cranium contains three components—brain tissue, blood, and cerebrospinal fluid (CSF)—that total ~1,700 mL in a typical adult: 1,400 mL brain (~80%), 150 mL blood (~10%), and 150 mL CSF (~10%). According to the Monro–Kellie doctrine, total intracranial volume is effectively fixed. When one component expands, CSF and venous blood...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Placebo Response in Acute and Prophylactic Treatment of Migraine: A Systematic Review and Meta-Analysis Covering 36 Years of Research.

Neurologic clinics·2025
Same author

Protocol of trans-Tasman feasibility randomised controlled trial of the Younger Women's Wellness After Breast Cancer (YWWACP) lifestyle intervention.

Pilot and feasibility studies·2022
Same author

[Diagnosis and treatment of acute ischemic insults].

Herz·2021
Same author

European Academy of Neurology guideline on the management of medication-overuse headache.

European journal of neurology·2020
Same author

MMW Fortschritte der Medizin·2018
Same author

Preventing dementia beyond treating hypertension.

European heart journal·2018

Related Experiment Video

Updated: Jun 28, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Migraine-associated risks and comorbidity.

H C Diener1, M Küper, T Kurth

  • 1Dept. of Neurology and Headache Center, University Duisburg-Essen, Hufelandstr. 55, 45147, Essen, Germany. hans.diener@uni.duisburg-essen.de

Journal of Neurology
|October 30, 2008
PubMed
Summary
This summary is machine-generated.

Migraine frequently co-occurs with other conditions, impacting treatment decisions. Understanding these comorbidities is crucial for effective migraine management and therapy selection.

Related Experiment Videos

Last Updated: Jun 28, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Area of Science:

  • Neurology
  • Clinical Medicine
  • Epidemiology

Background:

  • Migraine is a complex neurological disorder with significant impact on quality of life.
  • Co-occurring conditions (comorbidities) are common in migraine patients.
  • The relationship between migraine and comorbidities can be influenced by genetic or environmental factors.

Purpose of the Study:

  • To review significant comorbidities associated with migraine.
  • To discuss the implications of these comorbidities for migraine treatment strategies.
  • To highlight the need for robust epidemiological studies to establish true comorbidity.

Main Methods:

  • Literature review of studies on migraine and its comorbidities.
  • Analysis of the impact of comorbidities on acute and preventive treatment choices.
  • Discussion of the etiological basis of comorbidity.

Main Results:

  • Certain conditions frequently co-occur with migraine, influencing treatment selection.
  • The interplay between migraine and comorbidities requires careful consideration in clinical practice.
  • Establishing definitive comorbidity requires rigorous epidemiological evidence.

Conclusions:

  • Co-morbidity significantly affects the management of migraine.
  • Treatment strategies for migraine must account for co-existing conditions.
  • Further large-scale epidemiological research is essential to elucidate causal relationships in migraine comorbidity.